Artimplant Nine-Month Interim Report 2007 Conference Call on November 9, 11:00 AM (GMT+1)

VASTRA FROLUNDA, Sweden, Nov 07, 2007 (BUSINESS WIRE) -- Regulatory News: CEO Hans Rosen and CFO Lars-Johan Cederbrant present the nine-month Interim Report 2007 on November 9, 11:00 AM (GMT+1).

The presentation will be in Swedish.

Date: Friday, November 9 Time 11.00 CET (GMT+1) Dial in numbers: Swedish participants: +46 (0)8 505 598 53 UK participants: +44 (0)20 3043 2436 US participants: +1 866 458 40 87 A presentation in PDF format will be available on Artimplant's website www.artimplant.com a couple of minutes before the conference call starts.

Please note that Artimplant's nine-month interim report 2007 will be distributed with a press release on November 9 2007, 08:45 Central European Time (GMT+1).

About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon(R), meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This information was brought to you by Cision http://newsroom.cision.com SOURCE: Artimplant CONTACT: Artimplant Hans Rosen, CEO Tel: +46 (0)31-746 56 00/ +46 (0)708 58 34 70 hans.rosen@artimplant.com or Lars-Johan Cederbrant, CFO Tel: +46 (0)31-746 56 54/ +46 (0)703 01 68 54 lars-johan.cederbrant@artimplant.com www.artimplant.com Copyright Business Wire 2007 -0- KEYWORD: Sweden

Europe INDUSTRY KEYWORD: Health

Biotechnology

Dental SUBJECT CODE: Earnings